Concepedia

Matthew Kennedy

MK

51

Publications

4.4K

Citations

34

H-Index

1983

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Mayo Clinic

Vanderbilt University

Harvard University

Matthew Kennedy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and biochemistry.

ORCID

Top concepts

Publications per year

1983–2023

51

Publications

51

Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment

Colin Funk, Lena B. Funk, Matthew Kennedy et al. · The FASEB Journal · 1991 · 575 citations

, , +20

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

Simon Dujardin, Caitlin Commins, Aurélien Lathuilière et al. · Nature Medicine · 2020 · 427 citations · Full text

, , +9

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

, , +20

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 326 citations · Full text

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

, , +19

Rows per page

1–5 of 51